Wells Fargo
APLS

Wells Fargo’s Apellis Pharmaceuticals APLS Stock Holding History

Wells Fargo’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-21,700
Closed -$1.48M – 7451
2022
Q3 		$1.48M Buy
+21,700
New +$1.28M ﹤0.01% 2963

Other funds holding APLS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Wells Fargo's APLS Position: Q2 2026 in Review

Wells Fargo sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 8,592 shares — an estimated $346K sold.

Wells Fargo first reported a position in APLS in Q4 2017 and held it in 34 quarters. The position peaked at $18.1M in Q2 2025. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

  • Wells Fargo reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Wells Fargo sold 8,592 Apellis Pharmaceuticals shares in Q2 2026, an estimated $346K.
  • Wells Fargo first reported a position in Apellis Pharmaceuticals in Q4 2017 and held it in 34 quarters.
  • Wells Fargo's Apellis Pharmaceuticals position peaked at $18.1M in Q2 2025.
  • 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.